(KRYS) Krystal Biotech, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KRYS) Krystal Biotech, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Krystal Biotech, Inc. BCG Matrix helps you see how the company’s products or business units fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is used for strategy, portfolio review, and capital allocation, and this page already shows a real preview of the actual analysis. Purchase the full version to get the complete ready-to-use report.
Stars
Vyjuvek, FDA-approved 2023
Vyjuvek, approved by the FDA in 2023, is Krystal Biotech, Inc.’s only marketed product and its clearest Star. In 2025, it remained the company’s core revenue engine, with total product sales still driven almost entirely by beremagene geperpavec for dystrophic epidermolysis bullosa. Its U.S. approval gives Krystal a rare high-share niche in a severe rare-disease market.
Dystrophic epidermolysis bullosa franchise
Dystrophic epidermolysis bullosa (DEB) is a rare orphan disease with limited options, so Vyjuvek stands out as Krystal Biotech, Inc.'s first-in-class, locally delivered gene therapy. The FDA approved Vyjuvek for patients aged 6 months and older, giving it a clear edge in an underserved market. Even with a small patient base, first-mover status can support strong adoption and durable pricing power.
Redosable HSV-1 gene therapy platform
Krystal Biotech’s redosable HSV-1 platform uses a non-replicating vector, and Vyjuvek became the first FDA-approved topical gene therapy for dystrophic epidermolysis bullosa in 2023. The repeat-dosing model is a real edge in skin disease, where durable local delivery matters more than one-time use. That platform strength supports leadership beyond a single product.
U.S. commercial launch base
Vyjuvek turned Krystal Biotech, Inc. from a clinical-stage name into a commercial one, with 2024 revenue of about $290 million showing real U.S. launch scale. The U.S. commercial base already includes specialty distribution and field support, so each new prescription can add to a platform that is built, not still being built.
- Vyjuvek drives commercial-stage status.
- Specialty distribution is already set.
- Field support can scale with demand.
- More scripts can raise operating leverage.
Orphan dermatology leadership
Krystal Biotech’s orphan dermatology franchise fits a Star: it targets severe, rare skin diseases with high unmet need, and Vyjuvek, the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa, supports premium pricing and strong share in a niche market. As uptake grows, this mix of clear clinical need and concentrated demand can drive fast revenue expansion.
- Rare disease focus
- Premium orphan pricing
- Concentrated market share
- Growth stage still early
Vyjuvek Drives Krystal Biotech’s Growth Engine
Vyjuvek is Krystal Biotech, Inc.'s Star: the 2023 FDA-approved, first-in-class topical gene therapy for DEB, and still its only marketed product in 2025. Its rare-disease focus and redosable HSV-1 platform support strong share, premium pricing, and repeat use. With specialty distribution already in place, each new prescription can lift revenue fast.
What is included in the product
Detailed Word Document
Krystal Biotech’s BCG matrix maps its pipeline and commercial assets by growth potential, cash generation, and strategic priority.
Editable Excel File
One-page BCG matrix for Krystal Biotech, Inc. with a clean, C-level view of each business unit’s quadrant.
Reference Sources
Provides a credible source trail for Krystal Biotech, Inc., helping decision-makers verify key claims quickly and trust the analysis.
Cash Cows
Vyjuvek revenue engine
Vyjuvek is Krystal Biotech, Inc.'s main revenue engine and the closest thing it has to a cash cow. In 2025, it remained the company’s only marketed product and drove virtually all product revenue, helping fund pipeline work instead of draining cash. As adoption widens, Vyjuvek should keep turning in faster cash flow than newer programs consume.
Commercial manufacturing for Vyjuvek
Krystal Biotech’s proprietary cGMP manufacturing for Vyjuvek, its only commercial product, keeps production in-house and avoids third-party markups. As dose volume rises, fixed plant costs spread over more sales, so unit economics improve. That makes each incremental Vyjuvek sale more likely to convert into cash flow.
Specialty reimbursement base
Vyjuvek sits in a reimbursed orphan-drug niche, so once payers approve access, each new patient adds high-margin revenue with little extra sales cost. Krystal Biotech reported 2025 Vyjuvek growth against a rare-disease base, and the company ended the period with a strong cash position, supporting this cash-cow profile. The product’s specialty reimbursement path helps make sales repeatable and durable, not one-off.
High-margin rare-disease pricing
Rare-disease drugs can command premium pricing, and Krystal Biotech’s Vyjuvek fits that model. The U.S. list price is $24,250 per vial, and the company has reported gross margin above 90%, showing how a niche market can still throw off strong cash flow.
In FY2025, that pricing power helped support product revenue growth without needing mass-market volume. One clean takeaway: premium orphan-drug economics can keep margins high even with a small patient pool.
- Rare-disease pricing stays premium
- Vyjuvek supports margin strength
- Niche demand can still scale cash flow
Single-product commercialization
Krystal Biotech, Inc. runs a one-brand cash cow model: Vyjuvek is the sole commercial product, so selling, medical, and admin costs stay tightly centered instead of split across multiple launches. FY2024 product revenue reached about $277 million, showing how a single approved therapy can already fund the base business.
- One brand, one cost center
- Revenue scales faster than overhead
- Vyjuvek drives current cash flow
Vyjuvek Powers Krystal Biotech’s FY2025 Cash Cow
Vyjuvek is Krystal Biotech, Inc.'s only commercial product and the clear Cash Cow in FY2025, with about $277 million in FY2024 product revenue and strong gross margin above 90%. Its orphan-drug pricing, reimbursed access, and in-house cGMP manufacturing help convert each added patient into durable cash flow while keeping overhead tight.
| Metric | FY2025 |
|---|---|
| Commercial product | Vyjuvek |
| Product revenue | About $277 million |
| Gross margin | Above 90% |
| Model | One-brand cash cow |
Get Your Copy
Krystal Biotech, Inc. Reference Sources
This Krystal Biotech, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo content or hidden sections—just the full, polished file. It’s ready for immediate use in strategic planning, analysis, or presentations.
Dogs
No mature legacy brand
Krystal Biotech has one marketed product, VYJUVEK, so it has not built a large portfolio of older brands. That means there is no obvious underperforming legacy asset to sell or shut down. In BCG terms, the dog bucket is basically empty.
No broad low-growth segment
Krystal Biotech is still concentrated in rare-disease gene therapy, led by Vyjuvek, which posted 2024 revenue of about $280 million and kept the portfolio focused on one high-growth platform. It does not have a large, mature consumer or hospital franchise with slow growth and thin margins. So the classic BCG Dogs bucket is limited here, because the mix lacks a broad low-growth segment.
No second commercial product
Vyjuvek is Krystal Biotech, Inc.’s only approved and commercial product, so the Dogs bucket has little support here. In FY2024, Vyjuvek drove nearly all revenue, with no second product to show a low-share mature line. That makes the portfolio more concentrated than diversified, and it leaves little evidence of a weak legacy business.
No obsolete marketed pipeline asset
Krystal Biotech, Inc. has no clearly disclosed obsolete marketed asset draining capital, so a true Dogs label is weak here. The company’s disclosed programs are still active development candidates, with Vyjuvek as the only commercial product and no aging legacy drug portfolio to offset it.
- Active pipeline, not deadweight assets
- One marketed product supports growth
- No visible obsolete revenue drag
- Dog-classification fit is limited
No divestiture candidate
Krystal Biotech’s Dogs bucket is basically empty: the disclosed portfolio is still centered on growth assets, not mature cash traps. The company’s capital spend stays tied to pipeline and platform build-out, so there is no clear divestiture candidate in the current mix.
- Growth-led spend, not legacy drag
- No obvious low-growth asset to sell
- Dog quadrant remains minimal
That makes sense for a company still scaling its gene-therapy franchise, where R&D and commercialization support future value rather than fund a cleanup sale.
Krystal Biotech Has No “Dogs” to Cull—Just One Growing Product
Krystal Biotech has no meaningful Dogs bucket: Vyjuvek is still the only marketed product, so there is no aging, low-share legacy line to trim. FY2025 filings still point to a single-product mix, with commercial spend tied to growth, not cleanup.
| Dog signal | FY2025 view |
|---|---|
| Legacy brands | None disclosed |
| Marketed products | 1 |
| Dividend/asset drag | Not visible |
Question Marks
KB105, Phase I/II
KB105 is a Phase I/II gene therapy for autosomal recessive congenital ichthyosis, a rare skin disease affecting roughly 1 in 100,000 to 1 in 300,000 births. It has no commercial share yet, so it sits squarely in the Question Marks bucket. If later data show strong safety and efficacy, KB105 could move from early R&D spend to a future Star.
KB301, Phase I/II
KB301 is a Question Mark in Krystal Biotech, Inc.'s BCG Matrix because it targets wrinkles and damaged-skin signs in a large aesthetic market, but its share is still minimal as a Phase I/II asset. The company has reported no KB301 sales to date, so its upside depends on clinical proof and costly market entry in a crowded space.
KB407, preclinical
KB407 is Krystal Biotech’s cystic fibrosis program, and it is still preclinical in 2026, so the chance of clinical failure stays high. With no human efficacy, safety, or commercial data yet, it fits the BCG Question Mark profile: high upside if it works, but heavy R&D spend and uncertain returns. Krystal’s 2025 cash flow strength from Vyjuvek can fund this bet, but KB407 remains speculative.
KB104, preclinical
KB104 is a Question Mark in Krystal Biotech, Inc.'s BCG Matrix because it is still preclinical for Netherton syndrome and has not entered human efficacy testing. With no clinical data or market revenue yet, it needs heavy R&D spend before any share can form. In Krystal Biotech, Inc.'s 2025/2026 profile, that means high cash burn risk and no near-term sales pull.
- Preclinical only; no human efficacy data
- Netherton syndrome target; high unmet need
- Requires major investment before scale
KB5xx, discovery stage
KB5xx is a classic Question Mark in Krystal Biotech, Inc.’s BCG mix: it targets chronic skin disease, sits in early discovery, and has no clinical validation yet. That means high upside but very low current share, with value still tied to future data, not sales. In a pipeline led by Vyjuvek, KB5xx remains optionality, not earnings power.
- Early discovery only
- No clinical proof yet
- High upside, low share
- Pipeline option, not driver
Krystal Biotech’s Early-Stage Bets Could Drive Future Upside
Krystal Biotech, Inc.’s Question Marks are KB105, KB301, KB407, KB104, and KB5xx: all have little or no revenue and remain early-stage, so their share is still near zero. In 2025/2026, they need heavy R&D spend before any sales or market position can form. Their upside is real, but it depends on clinical success, not current cash flow.
| Program | Status | BCG role |
|---|---|---|
| KB105 | Phase I/II | Question Mark |
| KB301 | Phase I/II | Question Mark |
| KB407 | Preclinical | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.